Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | JUN | P05412 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334229 | 1.00 | MAPK8 (0.41) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL1033033 | 0.94 | GRM5 (0.39) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL1033032 | 0.94 | GRM5 (0.39) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL1034756 | 0.91 | GRM5 (0.39) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL1034758 | 0.91 | GRM5 (0.39) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL1334507 | 0.84 | MAPK8 (0.40) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL1334509 | 0.84 | MAPK8 (0.40) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL1334515 | 0.84 | MAPK8 (0.40) | MAPK8MAPK9GRM5MAPK10SYK | |
| SCHEMBL3418540 | 0.83 | GRM5 (0.43) | MAPK8GRM5MAPK10SYKJUN | |
| SCHEMBL3418538 | 0.83 | GRM5 (0.43) | MAPK8GRM5MAPK10SYKJUN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | MAPK8 3599/4885MAPK9 3460/4885GRM5 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.